CU20210063A7 - Antígeno recombinante para la inducción de respuesta inmune contra el virus zika - Google Patents

Antígeno recombinante para la inducción de respuesta inmune contra el virus zika

Info

Publication number
CU20210063A7
CU20210063A7 CU2021000063A CU20210063A CU20210063A7 CU 20210063 A7 CU20210063 A7 CU 20210063A7 CU 2021000063 A CU2021000063 A CU 2021000063A CU 20210063 A CU20210063 A CU 20210063A CU 20210063 A7 CU20210063 A7 CU 20210063A7
Authority
CU
Cuba
Prior art keywords
zika virus
induction
immune response
response against
recombinant antigen
Prior art date
Application number
CU2021000063A
Other languages
English (en)
Inventor
Darder Andy Jesús Bruno
Acosta Karem Cobas
González Lázaro Gil
Nieto Gerardo Enrique Guillén
Cruz Lisset Hermida
Vázquez Laura Lazo
Fuentes Yusleidi De La Caridad Pérez
Fernández Yaremis Romero
Portal Edith Suzarte
Prado Iris Valdés
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Priority to CU2021000063A priority Critical patent/CU20210063A7/es
Priority to AU2022320680A priority patent/AU2022320680A1/en
Priority to KR1020247005128A priority patent/KR20240038009A/ko
Priority to EP22757824.2A priority patent/EP4378475A1/en
Priority to CA3227009A priority patent/CA3227009A1/en
Priority to PCT/CU2022/050008 priority patent/WO2023006131A1/es
Priority to CN202280058340.2A priority patent/CN117979993A/zh
Publication of CU20210063A7 publication Critical patent/CU20210063A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

<p>Antígeno quimérico recombinante que comprende en su cadena polipeptídica un polipéptido correspondiente a los aminoácidos 2 al 104 de la proteína de la cápsida del virus zika o un polipéptido con una secuencia de aminoácidos con al menos 90 porciento de identidad con dicha región de la proteína de la cápsida. Composición vacunal que comprende dicho antígeno quimérico recombinante y un adyuvante vacunal farmacéuticamente aceptable, para la inducción de respuesta inmune contra el virus zika.</p>
CU2021000063A 2021-07-28 2021-07-28 Antígeno recombinante para la inducción de respuesta inmune contra el virus zika CU20210063A7 (es)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CU2021000063A CU20210063A7 (es) 2021-07-28 2021-07-28 Antígeno recombinante para la inducción de respuesta inmune contra el virus zika
AU2022320680A AU2022320680A1 (en) 2021-07-28 2022-07-21 Recombinant antigen for inducing an immune response against the zika virus
KR1020247005128A KR20240038009A (ko) 2021-07-28 2022-07-21 지카 바이러스에 대한 면역 반응을 유도하기 위한 재조합 항원
EP22757824.2A EP4378475A1 (en) 2021-07-28 2022-07-21 Recombinant antigen for inducing an immune response against the zika virus
CA3227009A CA3227009A1 (en) 2021-07-28 2022-07-21 Recombinant antigen for the induction of immune response against the zika virus
PCT/CU2022/050008 WO2023006131A1 (es) 2021-07-28 2022-07-21 Antigeno recombinante para la induccion de respuesta inmune contra el virus zika
CN202280058340.2A CN117979993A (zh) 2021-07-28 2022-07-21 用于诱导抗寨卡病毒的免疫反应的重组抗原

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2021000063A CU20210063A7 (es) 2021-07-28 2021-07-28 Antígeno recombinante para la inducción de respuesta inmune contra el virus zika

Publications (1)

Publication Number Publication Date
CU20210063A7 true CU20210063A7 (es) 2023-03-07

Family

ID=83005857

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2021000063A CU20210063A7 (es) 2021-07-28 2021-07-28 Antígeno recombinante para la inducción de respuesta inmune contra el virus zika

Country Status (7)

Country Link
EP (1) EP4378475A1 (es)
KR (1) KR20240038009A (es)
CN (1) CN117979993A (es)
AU (1) AU2022320680A1 (es)
CA (1) CA3227009A1 (es)
CU (1) CU20210063A7 (es)
WO (1) WO2023006131A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201806340YA (en) * 2016-02-17 2018-09-27 Curevac Ag Zika virus vaccine

Also Published As

Publication number Publication date
EP4378475A1 (en) 2024-06-05
WO2023006131A1 (es) 2023-02-02
CN117979993A (zh) 2024-05-03
KR20240038009A (ko) 2024-03-22
AU2022320680A1 (en) 2024-02-15
CA3227009A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
AR121931A1 (es) AGENTE INMUNOBIOLÓGICO Y MÉTODO DE UTILIZACIÓN DEL MISMO PARA INDUCIR INMUNIDAD ESPECÍFICA CONTRA EL VIRUS DEL SÍNDROME RESPIRATORIO AGUDO SEVERO SARS-CoV-2 (VARIANTES)
CL2022003757A1 (es) Vectores de aav que tienen una desamidación reducida de la cápside y sus usos (divisional solic 202002200).
CL2020002201A1 (es) Novedosos vectores de virus adenoasociado (aav), vectores de aav que tienen una desamidación reducida de la cápside y usos de estos.
RU2015132962A (ru) Иммуногенные композиции на основе вируса гриппа и их применение
JP2017530124A5 (es)
ES2150416T3 (es) Vacuna virica defectiva producida por una linea celular complementada en trans.
ES2673556T3 (es) Vacunas para el VHS-2
EA200801756A1 (ru) Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
CL2008002559A1 (es) Construccion que comprende un vector de fluorocarbono y un antigeno del virus de la influenza; composicion farmaceutica que lo comprende; y su uso para aumentar la respuesta inmunologica
EA201892735A1 (ru) Состав вакцины против hiv
JP2012501959A5 (es)
MX2021015465A (es) Vacuna para fiebre porcina africana.
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.
JP2020528911A5 (es)
CO6210756A2 (es) La proteina linfopoyetina estromal timica canina y usos de la misma
MX2023007395A (es) Vacunas del virus de la peste porcina africana (ppa).
RU2018130813A (ru) Вакцины против fmdv на основе рекомбинантного аденовирусного вектора и их применение
WO2017156511A8 (en) Live attenuated zika virus vaccine
PE20170429A1 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
AR108014A1 (es) Vacuna universal para enfermedades virales y método de vacunación
ZA202310663B (en) Immunogenic compositions to treat and prevent microbial infections
WO2018115509A3 (en) New flavivirus vaccine
CU20210063A7 (es) Antígeno recombinante para la inducción de respuesta inmune contra el virus zika
CO2023015564A2 (es) Virus quimérico de la enfermedad de newcastle que expresa las proteínas hn y f del apmv
AR095425A1 (es) Vacuna, uso y procedimiento para prevenir una infección por picornavirus